Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro

References

• Ambrosius LA, Dhawan D, Ramos-Vara JA, Ruple A, Knapp DW, Childress MO. 2018. Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma. Am J Vet Res. 79(6):643–649. doi: 10.2460/ajvr.79.6.643.
   PubMed Web of Science ®Google Scholar
• Aresu L, Marconato L, Martini V, Fanelli A, Licenziato L, Foiani G, Melchiotti E, Nicoletti A, Vascellari M. 2021. Prognostic value of PD-L1, PD-1 and CD8A in canine diffuse large B-cell lymphoma detected by RNAscope. Vet Sci. 8(7):120. doi: 10.3390/vetsci8070120.
   PubMed Web of Science ®Google Scholar
• Ariyarathna H, Thomson NA, Aberdein D, Perrott MR, Munday JS. 2020. Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. Vet Immunol Immunopathol. 230:110142. doi: 10.1016/j.vetimm.2020.110142.
   PubMed Web of Science ®Google Scholar
• Cascio MJ, Whitley EM, Sahay B, Cortes-Hinojosa G, Chang LJ, Cowart J, Salute M, Sayour E, Dark M, Sandoval Z, et al. 2021. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. Vet Immunol Immunopathol. 232:110169. doi: 10.1016/j.vetimm.2020.110169.
   PubMed Web of Science ®Google Scholar
• Choi JW, Withers SS, Chang H, Spanier JA, De La Trinidad VL, Panesar H, Fife BT, Sciammas R, Sparger EE, Moore PF, et al. 2020. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS One. 15(7):e0235518. doi: 10.1371/journal.pone.0235518.
   PubMed Web of Science ®Google Scholar
• Hartley G, Faulhaber E, Caldwell A, Coy J, Kurihara J, Guth A, Regan D, Dow S. 2017. Immune regulation of canine tumour and macrophage PD-L1 expression. Vet Comp Oncol. 15(2):534–549. doi: 10.1111/vco.12197.
   PubMed Web of Science ®Google Scholar
• Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, Sakai Y, Noguchi S, Kato M, Tsukui T, et al. 2020. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 10(1):18311. doi: 10.1038/s41598-020-75533-4.
   PubMed Web of Science ®Google Scholar
• Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. 2020. The role of PD-1 in acute and chronic infection. Front Immunol. 11:487. doi: 10.3389/fimmu.2020.00487.
   PubMed Web of Science ®Google Scholar
• Kumar SR, Kim DY, Henry CJ, Bryan JN, Robinson KL, Eaton AM. 2017. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors. Vet Comp Oncol. 15(4):1527–1536. doi: 10.1111/vco.12297.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2(3):261–268. doi: 10.1038/85330.
   PubMed Web of Science ®Google Scholar
• Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi M, Takagi S, Kagawa Y, Nakajima C, Suzuki Y, Murata S, et al. 2014. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS One. 9(6):e98415. doi: 10.1371/journal.pone.0098415.
   PubMed Web of Science ®Google Scholar
• Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, et al. 2021. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol. 5(1):10. doi: 10.1038/s41698-021-00147-6.
   PubMed Web of Science ®Google Scholar
• Maekawa N, Konnai S, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Takagi S, Kagawa Y, Nakajima C, Suzuki Y, et al. 2016. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS One. 11(6):e0157176. doi: 10.1371/journal.pone.0157176.
   PubMed Web of Science ®Google Scholar
• Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, et al. 2017. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Sci Rep. 7(1):8951. doi: 10.1038/s41598-017-09444-2.
   PubMed Web of Science ®Google Scholar
• Minoli L, Licenziato L, Kocikowski M, Cino M, Dziubek K, Iussich S, Fanelli A, Morello E, Martano M, Hupp T, et al. 2022. Development of monoclonal antibodies targeting canine PD-L1 and PD-1 and their clinical relevance in canine apocrine gland anal sac adenocarcinoma. Cancers (Basel). 14:6188. doi: 10.3390/cancers14246188.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. 2014. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2(4):361–370. doi: 10.1158/2326-6066.CIR-13-0127.
   PubMed Web of Science ®Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. 2020. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 30(6):507–519. doi: 10.1038/s41422-020-0337-2.
   PubMed Web of Science ®Google Scholar
• Nemoto Y, Shosu K, Okuda M, Noguchi S, Mizuno T. 2018. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1. Vet Immunol Immunopathol. 198:19–25. doi: 10.1016/j.vetimm.2018.02.007.
   PubMed Web of Science ®Google Scholar
• Pantelyushin S, Ranninger E, Guerrera D, Hutter G, Maake C, Markkanen E, Bettschart-Wolfensberger R, Rohrer Bley C, Laubli H, Vom Berg J. 2021. Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. Cancers (Basel). 13:785. doi: 10.3390/cancers13040785.
   PubMed Web of Science ®Google Scholar
• Phakham T, Boonkrai C, Wongtangprasert T, Audomsun T, Attakitbancha C, Saelao P, Muanwien P, Sooksai S, Hirankarn N, Pisitkun T. 2022. Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development. Sci Rep. 12(1):17792. doi: 10.1038/s41598-022-20560-6.
   PubMed Web of Science ®Google Scholar
• Pinard CJ, Hocker SE, Poon AC, Inkol JM, Matsuyama A, Wood RD, Wood GA, Woods JP, Mutsaers AJ. 2022. Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines. Vet Immunol Immunopathol. 243:110367. doi: 10.1016/j.vetimm.2021.110367.
   PubMed Web of Science ®Google Scholar
• Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T, Martinez A, Nuciforo P, Comerma L, Alos L, et al. 2017. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77(13):3540–3550. doi: 10.1158/0008-5472.CAN-16-3556.
   PubMed Web of Science ®Google Scholar
• Shosu K, Sakurai M, Inoue K, Nakagawa T, Sakai H, Morimoto M, Okuda M, Noguchi S, Mizuno T. 2016. Programmed cell death ligand 1 expression in canine cancer. In Vivo. 30:195–204.
   PubMed Web of Science ®Google Scholar
• Stevenson VB, Perry SN, Todd M, Huckle WR, LeRoith T. 2021. PD-1, PD-L1, and PD-L2 gene expression and tumor infiltrating lymphocytes in canine melanoma. Vet Pathol. 58(4):692–698. doi: 10.1177/03009858211011939.
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. 2018. Regulation and function of the PD-L1 checkpoint. Immunity. 48(3):434–452. doi: 10.1016/j.immuni.2018.03.014.
   PubMed Web of Science ®Google Scholar
• Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, et al. 2018. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 131(16):1809–1819. doi: 10.1182/blood-2017-07-796342.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara H, et al. 2015. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35 Suppl: S185–S198. doi: 10.1016/j.semcancer.2015.03.004.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 169(10):5538–5545. doi: 10.4049/jimmunol.169.10.5538.
   PubMed Web of Science ®Google Scholar